Home / News / BioBlast™ Archive

BIOSIMILARS UPDATES

Our BioBlast™ Archive

Explore biologics and biosimilars news updates (BioBlast®) at Pearce IP

BioBlast w/e 26 May 23

26 MAY 2023 | EU | Celltrion files MAA with EMA for biosimilar to Janssen’s Stelara® (ustekinumab) Korea Biomed has reported that Celltrion filed a marketing authorisation application with the EMA for CT-P43, its biosimilar to Janssen’s Stelara®...

BioBlast w/e 22 May 23

22 MAY 2023 | US | Janssen and Amgen settle Stelara® (ustekinemab) biosimilar patent dispute The US District Court of Delaware has dismissed with prejudice.  The parties agreed to dismiss the action with prejudice and each party will bear its...

BioBlast w/e 12 May 23

11 MAY 2023| EU | Celltrion to supply Vegzelma® (bevacizumab) in Italy and Belgium Korea Biomed has reported that Celltrion Healthcare has won bids to supply Vegzelma®, biosimilar to Genentech’s Avastin® (bevacizumab), in Italy and Belgium to...

BioBlast w/e 05 May 23

04 MAY 2023 | CN | Boan Biotech commences phase III clinical trials for Prolia®/Xgeva® (denosumab) biosimilar Luye Pharma announced that it has enrolled its first subject in an international multi-center Phase 3 clinical study for its internally...

BioBlast w/e 28 Apr 23

28 April 2023 | US | FDA advisory committee supports approval of Merck’s Lynparza® (olaparib) combination for first line treatment of prostate cancer Merck announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to support...

BioBlast w/e 21 Apr 23

20 April 2023 | CA | New indication alert: Health Canada issues notice of compliance for Regeneron/Sanofi’s Dupixent® (dupilumab) in children > 6 months Sanofi and Regeneron announced that Health Canada issued a Notice of Compliance for...

BioBlast f/e 14 Apr 23

Significant biosimilar activities this fortnight include: 13 April 2023 | US | Alvotech CRL provided to FDA regarding high concentration buffer free biosimilar adalimumab 12 April 2023 | AU | Samsung Bioepis files opposition to Janssen’s...

BioBlast w/e 31 Mar 23: Humira® AU price reduction | EMA recommends Samsung’s EPYSQLI™ eculizumab | US Supreme Court hears Amgen v Sanofi | Eli Lilly $1B mAb manufacture investment in Ireland | Daiichi Enhertu® JP approval | Coya and Dr. Reddy’s ww development agreement … and more!

Significant biosimilar activities this week include:01 April 2023 | AU | Humira® 24.39% PBS price drop 30 March 2023 | EU | EMA CHMP gives nod to Samsung Bioepis’ Epysqli™ eculizumab biosimilar 29 March 2023 | AU | Cipla/Alvotech’s biosimilar...

Meet our BioBlast™ authors

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Naomi and Emily author the weekly BioBlast™ update, ensuring that everyone is kept up to date with the latest happenings within the biosimilars industry.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.